Parexel expects to hit the $2B mark in fiscal 2015

Parexel ($PRXL) figures it can rake in more than $2 billion in revenue in the next fiscal year, banking on a solid book-to-bill ratio and increasing global demand to deliver an all-time high.

The CRO is expecting between $2.1 billion and $2.2 billion in fiscal 2015, which begins July 1, good for more than 10% growth over the company's projected 2014 haul of $1.9 billion.

The forecast signals another double-digit-growth year for the Boston company, which leapt 12% last year. Parexel has attributed its steady growth to maintaining relationships with Big Pharma but also gaining momentum among small and mid-sized drugmakers.

Last quarter, the CRO brought in $492.4 million in service revenue, about 8% above the same period last year. Parexel's sizable clinical research segment led the way, growing 9% to $373.2 million, while its recently rebranded informatics business jumped 9% to $67.3 million and its consulting branch ticked up 2% to $51.8 million. The company's net income leapt 18% to $34.7 million on the quarter.

Parexel is in the midst of a sweeping rebranding effort through which it is looking to better entrench itself in the high-stakes competition between the largest players in an increasingly top-heavy market. The goal is to better establish Parexel's disparate offerings as a continuum of services, CEO Josef von Rickenbach has said, and the CRO has retitled its banner eClinical business to bear the company's name.

- read the statement

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

Aetion has raised $50 million so far, and it plans to enhance its platform to support more complex therapeutic areas and expand its team.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.